BYSI Stock Analysis: Buy, Sell, or Hold?
BYSI - BeyondSpring Inc. Ordinary Shares
$0.43
-0.01 (-3.15%)
▼
5d:
-22.91%
30d:
-40.54%
90d:
-63.15%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When BYSI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BYSI is down 22.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BYSI is down 22.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BYSI is currently trading at $0.43, which is considered oversold relative to its 30-day fair value range of $0.54 to $0.81.
Technical Outlook: Technically, BYSI is in a strong downtrend. The price is currently testing key support at $0.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: BYSI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.25 (+190.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BYSI is in a strong downtrend. The price is currently testing key support at $0.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: BYSI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.25 (+190.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.54 -
$0.81
Company Quality Score
40/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 190.0% below Wall St target ($1.25)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.54 -
$0.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.42
Resistance Level
$0.66
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.54
Wall Street Target
$1.25
(+190.0%)
Revenue Growth (YoY)
14.3%
Share & Embed Analysis
Last updated: October 24, 2026 2:45 PM ET
Data refreshes hourly during market hours. Next update: 3:45 PM
Data refreshes hourly during market hours. Next update: 3:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BYSI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 60 HOLD |
